Mergers & Acquisitions ·
Passage Bio, Inc. entered into a merger agreement on June 24, 2026, with Remix Therapeutics, Inc., where Remix will…
PASGPassage BIO, Inc.
Passage Bio, Inc. entered into a merger agreement on June 24, 2026, with Remix Therapeutics, Inc., where Remix will become a wholly owned subsidiary of Passage Bio. Remix is valued at $226 million, while Passage Bio is valued at approximately $20 million. The deal includes a $100 million concurrent financing for Remix and the issuance of Contingent Value Rights (CVRs) to Passage Bio stockholders. Peter Smith, Ph.D., will serve as CEO of the combined company, and the board will consist of nine members designated by Remix. Additionally, Passage Bio terminated its development services agreement with Catalent Maryland, Inc. and its license agreement with the University of Pennsylvania for the PBFT02 program. Passage Bio is a biotechnology company focused on gene therapy.